Drug Delivery Directly to the Tumor – Innovation Blog | Mass General Brigham
PanTher founder Dr. David Ting, MD was featured in the Mass General Brigham’s Innovation Blog as part of a series about companies that are Getting Great Science to Market. “I think there are certain cancers that this local delivery approach is highly relevant for,” says Ting. “This includes pancreas cancer, esophageal cancer and potentially mesothelioma—the ones we can’t get drugs into very well.”
Read More about Drug Delivery Directly to the Tumor – Innovation Blog | Mass General Brigham
Laura Indolfi Presents at MassBio 2019 Annual Meeting
Massachusetts is the epicenter of startup creation for biotech, but it’s not always easy to go from research to commercialization. Come hear founders and industry leaders on the panel “Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies” offer lessons learned on intelligently scaling your company amid rapid growth including when to partner, sell or IPO, or when to build or buy preclinical, manufacturing, and clinical development capabilities. PanTher CEO Laura Indolfi will be one of the panelists for this illuminating discussion hosted by the Massachusetts Biotechnology Council.
Read More about Laura Indolfi Presents at MassBio 2019 Annual Meeting
Startup Spotlight: PanTher’s drug-delivery patch aims to knock down the ‘wall’ of pancreatic cancer
PanTher was featured on the STAT Startup Spotlight in December. Kate Sheridan provided an overview of the company technology and its status highlighting the interest of large pharma companies into the disruptive technology of our early-stage start-up. “Wherever there has been a stage for biotech entrepreneurs this fall, Laura Indolfi has appeared. And wherever she is, major pharmaceutical companies have been, too. Indolfi’s company, Cambridge, Mass.-based PanTher Therapeutics, has already received awards linked to Bristol-Myers Squibb and Johnson & Johnson. And on Tuesday, she competed for — and won — one of Amgen’s Golden Tickets — a one-year pass into LabCentral, the noted Cambridge lab-sharing space where PanTher is already headquartered.”
PanTher Therapeutics Announces Agreement with MD Anderson Cancer Center and Appointment of Senior Clinical Advisor
PanTher Therapeutics, the biotech company developing drug-delivery platforms for unresectable, locally advanced solid tumors, today announced an agreement with The University of Texas MD Anderson Cancer Center and the appointment of a new senior clinical advisor. The collaboration will support preclinical testing of PanTher’s lead product for pancreatic cancer, PTM-101, and is intended to demonstrate readiness for future human clinical trials.
CEO of PanTher Therapeutics to speak at “How to advance in Biotech”
Drug development relies on years of experience across the industry and exposure to multiple upstream and downstream elements in order to be prepared for the challenges in our unique field. If you’re a young person working in drug or device development, what are the roles that will give you a broad set of experiences to prepare you for an eventual CEO role? Join us as we will discuss what needs to be done, and where you should put your energy today to be a leader in the field tomorrow. Hear from experts across the industry, from the investors who know what they’re looking for when it comes to biotech leadership, the experienced CEO’s who know what it takes, and some of the young people on the front lines of successful biotech startups.
Read More about CEO of PanTher Therapeutics to speak at “How to advance in Biotech”
A Simple Piece of Plastic Could Slash Pancreatic Cancer Death Rates
The pancreas is located in the middle of a person’s belly, surrounded by other vital organs like the liver and stomach. This both makes it extremely hard for surgeons to remove the tumor and easier for it to metastasize and spread. Chemotherapy–which sends toxic drugs throughout the body to reach the tumor site–is still often the only option, and it’s not even very effective because pancreatic tumors have few blood vessels to take up the drugs. “To me, it seems very counterintuitive to have a whole body treatment to target a specific organ,” says CEO Dr. Laura Indolfi.
